Form 4: Apogee Therapeutics CFO Sells Shares, Receives Options

Apogee Therapeutics CFO Jane Henderson reported sales of 8,000 common shares and the grant of new stock options for 83,690 shares.

Summary

• Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc. (APGE), reported transactions involving the company's common stock.
• She sold a total of 8,000 shares of common stock across three separate transactions in early January 2026.
• These sales were executed pursuant to a Rule 10b5-1 trading plan that was adopted on September 27, 2024.
• On January 2, 2026, 1,920 shares were sold at a weighted average price of $74.13 per share, with individual transaction prices ranging from $73.67 to $74.65.
• Also on January 2, 2026, an additional 4,080 shares were sold at a weighted average price of $75.20 per share, with prices ranging from $74.73 to $75.67.
• On January 6, 2026, 2,000 shares were sold at a price of $80.00 per share.
• Following these reported sales, her direct beneficial ownership of common stock stands at 185,371 shares.
• Concurrently, on January 2, 2026, she was granted a stock option to purchase 83,690 shares of the company's common stock with an exercise price of $75.78.
• This stock option will vest in forty-eight equal monthly installments over a four-year period from the grant date, contingent upon her continued service to the Issuer.
• The granted stock option has an expiration date of January 2, 2036.

Sentiment

Score: 4

Explanation: The sentiment is mixed. While the insider selling of shares could be perceived negatively, it was conducted under a pre-arranged 10b5-1 plan, which mitigates some concerns. The simultaneous grant of a significant number of new stock options to the CFO indicates continued long-term alignment with the company's performance and future growth.

Positives

• The grant of 83,690 stock options to the CFO aligns her long-term incentives with the company's performance and shareholder value.
• The stock option has a 10-year expiration date (January 2, 2036), providing a substantial long-term incentive horizon for the CFO.

Negatives

• CFO Jane Henderson sold a total of 8,000 shares of common stock in early January 2026.
• The sales occurred at prices ranging from $73.67 to $80.00 per share, representing a reduction in her direct common stock holdings.

Risks

• Insider selling, even when conducted under a Rule 10b5-1 plan, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence or a desire by the executive to diversify personal holdings.

Future Outlook

The stock option granted to the CFO vests over a four-year period, indicating a long-term commitment to the company's future performance, subject to her continued service.

Industry Context

This Form 4 filing reflects routine insider transactions for a publicly traded biotechnology company, where equity compensation and planned stock sales are common practices for executives.

Corporate Governance

Stakeholder Impact

• Shareholders may view insider selling with caution, but the existence of a Rule 10b5-1 plan and the simultaneous grant of new stock options provide context, suggesting planned diversification and continued long-term alignment of the CFO's interests with the company's performance.

Next Steps

• The granted stock option will vest in forty-eight equal monthly installments over a four-year period from January 2, 2026, subject to the CFO's continued service.

Key Dates

Recommendation

The filing presents mixed signals. While the CFO's sale of 8,000 shares might typically be a negative indicator, it was conducted under a pre-established 10b5-1 trading plan, which suggests a planned diversification rather than a reaction to new negative information. Simultaneously, the grant of 83,690 new stock options with a four-year vesting schedule demonstrates continued long-term commitment and alignment of the CFO's interests with the company's future performance. Given these offsetting factors, a 'hold' recommendation is appropriate as there isn't a clear strong bullish or bearish signal from this specific insider transaction report alone.

Keywords

Apogee Therapeutics, APGE, Insider Trading, Form 4, Stock Sale, Stock Option, CFO, Rule 10b5-1 Plan, Equity Compensation